Petelina T I, Gapon L I, Bakhmatova Iu A, Zhevagina I A, Kalinina V A, Todosiĭchuk V V, Kuznetsov V A
Kardiologiia. 2005;45(8):17-22.
Efficacy of combination of trimetazidine (60 mg/day) and enalapril in patients with stable effort angina and metabolic syndrome was assessed in a randomized placebo controlled study of 64 patients. Anti-ischemic activity of trimetazidine was found to be significant. It was most pronounced in patients with abnormal 24-hour blood pressure index, waist/hip circumference ratio >1.0 at the background of satisfactory clinical and laboratory compensation of type 2 diabetes.
在一项针对64例患者的随机安慰剂对照研究中，评估了曲美他嗪（60毫克/天）与依那普利联合应用于稳定型劳力性心绞痛合并代谢综合征患者的疗效。发现曲美他嗪具有显著的抗缺血活性。在24小时血压指数异常、2型糖尿病临床和实验室指标得到满意控制的情况下，腰臀围比>1.0的患者中这种活性最为明显。
